A BILL 
To lower the cost of prescription drugs, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Competition Prescription Act of 2019’’. 
5
(b) TABLE OF CONTENTS.—The table of contents for 
6
this Act is as follows: 
7
Sec. 1. Short title; table of contents. 
TITLE I—ELIMINATING DELAYS OF GENERIC DRUGS AND 
BIOSIMILAR PRODUCTS 
02:33 Aug 09, 2019
H3947
2 
•HR 3947 IH
Sec. 101. Actions for delays of generic drugs and biosimilar biological products. 
Sec. 102. REMS approval process for subsequent filers. 
TITLE II—INCREASING ACCESS TO DRUGS AND BIOSIMILAR 
PRODUCTS 
Sec. 201. Expedited development and priority review for generic complex drug 
products. 
Sec. 202. Increasing pharmaceutical options to treat an unmet medical need. 
Sec. 203. Preemption of State barriers to the substitution of biosimilar prod-
ucts. 
Sec. 204. Expedited process for biological products authorized for marketing in 
European Union. 
TITLE III—PRESCRIPTION DRUG PRICING AND COMPETITION 
Sec. 301. Medicare drug coverage. 
Sec. 302. Fee transparency between pharmacies and PBMs. 
Sec. 303. Sunset of limit on maximum rebate amount for single source drugs 
and innovator multiple source drugs. 
Sec. 304. Regulation of manufacturer-sponsored copay contributions. 
TITLE IV—PATENT DISCLOSURE REQUIREMENTS 
Sec. 401. Patent disclosure and transparency requirements. 
Sec. 402. Antitrust exemption for health insurance issuers to negotiate whole-
sale acquisition prices of prescription drugs purchased from 
drug manufacturers. 
Sec. 403. Fair treatment of Medicare part B billing codes for the prescribing 
of biosimilars. 
TITLE V—FIXING GLOBAL FREELOADING 
Sec. 501. Chief Pharmaceutical Negotiator in the Office of the United States 
Trade Representative. 
TITLE I—ELIMINATING DELAYS 
1
OF GENERIC DRUGS AND BIO-
2
SIMILAR PRODUCTS 
3
SEC. 101. ACTIONS FOR DELAYS OF GENERIC DRUGS AND 
4
BIOSIMILAR BIOLOGICAL PRODUCTS. 
5
(a) DEFINITIONS.—In this section— 
6
(1) the term ‘‘commercially reasonable, market- 
7
based terms’’ means— 
8
(A) a nondiscriminatory price for the sale 
9
of the covered product at or below, but not 
10
02:33 Aug 09, 2019
H3947
3 
•HR 3947 IH
greater than, the most recent wholesale acquisi-
1
tion cost for the drug, as defined in section 
2
1847A(c)(6)(B) of the Social Security Act (42 
3
U.S.C. 1395w–3a(c)(6)(B)); 
4
(B) a schedule for delivery that results in 
5
the transfer of the covered product to the eligi-
6
ble product developer consistent with the timing 
7
under subsection (b)(2)(A)(iv); and 
8
(C) no additional conditions are imposed 
9
on the sale of the covered product; 
10
(2) the term ‘‘covered product’’— 
11
(A) means— 
12
(i) any drug approved under sub-
13
section (c) or (j) of section 505 of the Fed-
14
eral Food, Drug, and Cosmetic Act (21 
15
U.S.C. 355) or biological product licensed 
16
under subsection (a) or (k) of section 351 
17
of the Public Health Service Act (42 
18
U.S.C. 262); 
19
(ii) any combination of a drug or bio-
20
logical product described in clause (i); or 
21
(iii) when reasonably necessary to 
22
support approval of an application under 
23
section 505 of the Federal Food, Drug, 
24
and Cosmetic Act (21 U.S.C. 355), or sec-
25
02:33 Aug 09, 2019
H3947
4 
•HR 3947 IH
tion 351 of the Public Health Service Act 
1
(42 U.S.C. 262), as applicable, or other-
2
wise meet the requirements for approval 
3
under either such section, any product, in-
4
cluding any device, that is marketed or in-
5
tended for use with such a drug or biologi-
6
cal product; and 
7
(B) does not include any drug or biological 
8
product that appears on the drug shortage list 
9
in effect under section 506E of the Federal 
10
Food, Drug, and Cosmetic Act (21 U.S.C. 
11
356e), unless— 
12
(i) the drug or biological product has 
13
been on the drug shortage list in effect 
14
under such section 506E continuously for 
15
more than 6 months; or 
16
(ii) the Secretary determines that in-
17
clusion of the drug or biological product as 
18
a covered product is likely to contribute to 
19
alleviating or preventing a shortage; 
20
(3) the term ‘‘device’’ has the meaning given 
21
the term in section 201 of the Federal Food, Drug, 
22
and Cosmetic Act (21 U.S.C. 321); 
23
(4) the term ‘‘eligible product developer’’ means 
24
a person that seeks to develop a product for ap-
25
02:33 Aug 09, 2019
H3947
5 
•HR 3947 IH
proval pursuant to an application for approval under 
1
subsection (b)(2) or (j) of section 505 of the Federal 
2
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or 
3
for licensing pursuant to an application under sec-
4
tion 351(k) of the Public Health Service Act (42 
5
U.S.C. 262(k)); 
6
(5) the term ‘‘license holder’’ means the holder 
7
of an application approved under subsection (c) or 
8
(j) of section 505 of the Federal Food, Drug, and 
9
Cosmetic Act (21 U.S.C. 355) or the holder of a li-
10
cense under subsection (a) or (k) of section 351 of 
11
the Public Health Service Act (42 U.S.C. 262) for 
12
a covered product; 
13
(6) the term ‘‘REMS’’ means a risk evaluation 
14
and mitigation strategy under section 505–1 of the 
15
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
16
355–1); 
17
(7) the term ‘‘REMS with ETASU’’ means a 
18
REMS that contains elements to assure safe use 
19
under section 505–1(f) of the Federal Food, Drug, 
20
and Cosmetic Act (21 U.S.C. 355–1(f)); 
21
(8) the term ‘‘Secretary’’ means the Secretary 
22
of Health and Human Services; 
23
(9) the term ‘‘single, shared system of elements 
24
to assure safe use’’ means a single, shared system 
25
02:33 Aug 09, 2019
H3947
6 
•HR 3947 IH
of elements to assure safe use under section 505– 
1
1(f) of the Federal Food, Drug, and Cosmetic Act 
2
(21 U.S.C. 355–1(f)); and 
3
(10) the term ‘‘sufficient quantities’’ means an 
4
amount of a covered product that the eligible prod-
5
uct developer determines allows it to— 
6
(A) conduct testing to support an applica-
7
tion under— 
8
(i) subsection (b)(2) or (j) of section 
9
505 of the Federal Food, Drug, and Cos-
10
metic Act (21 U.S.C. 355); or 
11
(ii) section 351(k) of the Public 
12
Health Service Act (42 U.S.C. 262(k)); 
13
and 
14
(B) fulfill any regulatory requirements re-
15
lating to approval of such an application. 
16
(b) CIVIL ACTION FOR FAILURE TO PROVIDE SUFFI-
17
CIENT QUANTITIES OF A COVERED PRODUCT.— 
18
(1) IN GENERAL.—An eligible product developer 
19
may bring a civil action against the license holder 
20
for a covered product seeking relief under this sub-
21
section in an appropriate district court of the United 
22
States alleging that the license holder has declined 
23
to provide sufficient quantities of the covered prod-
24
02:33 Aug 09, 2019
H3947
7 
•HR 3947 IH
uct to the eligible product developer on commercially 
1
reasonable, market-based terms. 
2
(2) ELEMENTS.— 
3
(A) IN GENERAL.—To prevail in a civil ac-
4
tion brought under paragraph (1), an eligible 
5
product developer shall prove, by a preponder-
6
ance of the evidence— 
7
(i) that— 
8
(I) the covered product is not 
9
subject to a REMS with ETASU; or 
10
(II) if the covered product is sub-
11
ject to a REMS with ETASU— 
12
(aa) the eligible product de-
13
veloper has obtained a covered 
14
product authorization from the 
15
Secretary in accordance with sub-
16
paragraph (B); and 
17
(bb) the eligible product de-
18
veloper has provided a copy of 
19
the covered product authorization 
20
to the license holder; 
21
(ii) that, as of the date on which the 
22
civil action is filed, the product developer 
23
has not obtained sufficient quantities of 
24
02:33 Aug 09, 2019
H3947
8 
•HR 3947 IH
the covered product on commercially rea-
1
sonable, market-based terms; 
2
(iii) that the eligible product developer 
3
has requested to purchase sufficient quan-
4
tities of the covered product from the li-
5
cense holder; and 
6
(iv) that the license holder has not de-
7
livered to the eligible product developer 
8
sufficient quantities of the covered product 
9
on commercially reasonable, market-based 
10
terms— 
11
(I) for a covered product that is 
12
not subject to a REMS with ETASU, 
13
by the date that is 31 days after the 
14
date on which the license holder re-
15
ceived the request for the covered 
16
product; and 
17
(II) for a covered product that is 
18
subject to a REMS with ETASU, by 
19
31 days after the later of— 
20
(aa) the date on which the 
21
license holder received the re-
22
quest for the covered product; or 
23
(bb) the date on which the 
24
license holder received a copy of 
25
02:33 Aug 09, 2019
H3947
9 
•HR 3947 IH
the covered product authorization 
1
issued by the Secretary in ac-
2
cordance with subparagraph (B). 
3
(B) AUTHORIZATION FOR COVERED PROD-
4
UCT SUBJECT TO A REMS WITH ETASU.— 
5
(i) REQUEST.—An eligible product de-
6
veloper may submit to the Secretary a 
7
written request for the eligible product de-
8
veloper to be authorized to obtain suffi-
9
cient quantities of an individual covered 
10
product subject to a REMS with ETASU. 
11
(ii) AUTHORIZATION.—Not later than 
12
120 days after the date on which a request 
13
under clause (i) is received, the Secretary 
14
shall, by written notice, authorize the eligi-
15
ble product developer to obtain sufficient 
16
quantities of an individual covered product 
17
subject to a REMS with ETASU for pur-
18
poses of— 
19
(I) development and testing that 
20
does not involve human clinical trials, 
21
if the eligible product developer has 
22
agreed to comply with any conditions 
23
the Secretary determines necessary; or 
24
02:33 Aug 09, 2019
H3947
10 
•HR 3947 IH
(II) development and testing that 
1
involves human clinical trials, if the 
2
eligible product developer has— 
3
(aa)(AA) submitted proto-
4
cols, 
informed 
consent 
docu-
5
ments, and informational mate-
6
rials for testing that include pro-
7
tections that provide safety pro-
8
tections comparable to those pro-
9
vided by the REMS for the cov-
10
ered product; or 
11
(BB) otherwise satisfied the 
12
Secretary that such protections 
13
will be provided; and 
14
(bb) met any other require-
15
ments the Secretary may estab-
16
lish. 
17
(iii) NOTICE.—A covered product au-
18
thorization issued under this subparagraph 
19
shall state that the provision of the covered 
20
product by the license holder under the 
21
terms of the authorization will not be a 
22
violation of the REMS for the covered 
23
product. 
24
02:33 Aug 09, 2019
H3947
11 
•HR 3947 IH
(3) AFFIRMATIVE DEFENSE.—In a civil action 
1
brought under paragraph (1), it shall be an affirma-
2
tive defense, on which the defendant has the burden 
3
of persuasion by a preponderance of the evidence— 
4
(A) that, on the date on which the eligible 
5
product developer requested to purchase suffi-
6
cient quantities of the covered product from the 
7
license holder— 
8
(i) neither the license holder nor any 
9
of its agents, wholesalers, or distributors 
10
was engaged in the manufacturing or com-
11
mercial marketing of the covered product; 
12
and 
13
(ii) neither the license holder nor any 
14
of its agents, wholesalers, or distributors 
15
otherwise had access to inventory of the 
16
covered product to supply to the eligible 
17
product developer on commercially reason-
18
able, market-based terms; 
19
(B) that— 
20
(i) the license holder sells the covered 
21
product through agents, distributors, or 
22
wholesalers; 
23
(ii) the license holder has placed no 
24
restrictions, explicit or implicit, on its 
25
02:33 Aug 09, 2019
H3947
12 
•HR 3947 IH
agents, distributors, or wholesalers to sell 
1
covered products to eligible product devel-
2
opers; and 
3
(iii) the covered product can be pur-
4
chased by the eligible product developer in 
5
sufficient quantities on commercially rea-
6
sonable, market-based terms from the 
7
agents, distributors, or wholesalers of the 
8
license holder; or 
9
(C) that the license holder made an offer 
10
to sell sufficient quantities of the covered prod-
11
uct to the eligible product developer at commer-
12
cially reasonable market-based terms— 
13
(i) for a covered product that is not 
14
subject to a REMS with ETASU, by the 
15
date that is 14 days after the date on 
16
which the license holder received the re-
17
quest for the covered product, and the eli-
18
gible product developer did not accept such 
19
offer by the date that is 7 days after the 
20
date on which the eligible product devel-
21
oper received such offer from the license 
22
holder; or 
23
(ii) for a covered product that is sub-
24
ject to a REMS with ETASU, by the date 
25
02:33 Aug 09, 2019
H3947
13 
•HR 3947 IH
that is 20 days after the date on which the 
1
license holder received the request for the 
2
covered product, and the eligible product 
3
developer did not accept such offer by the 
4
date that is 10 days after the date on 
5
which the eligible product developer re-
6
ceived such offer from the license holder. 
7
(4) METHODS
FOR
TRANSMISSION
OF
RE-
8
QUESTS FOR COVERED PRODUCTS.—A written re-
9
quest for a covered product, offer to sell a covered 
10
product, or acceptance of such an offer between the 
11
eligible product developer and the license holder 
12
shall be made by— 
13
(A) certified or registered mail with return 
14
receipt requested; 
15
(B) personal delivery; or 
16
(C) electronic means. 
17
(5) REMEDIES.— 
18
(A) IN GENERAL.—If an eligible product 
19
developer prevails in a civil action brought 
20
under paragraph (1), the court shall— 
21
(i) order the license holder to provide 
22
to the eligible product developer without 
23
delay sufficient quantities of the covered 
24
02:33 Aug 09, 2019
H3947
14 
•HR 3947 IH
product on commercially reasonable, mar-
1
ket-based terms; 
2
(ii) award to the eligible product de-
3
veloper reasonable attorney’s fees and costs 
4
of the civil action; and 
5
(iii) award to the eligible product de-
6
veloper a monetary amount sufficient to 
7
deter the license holder from failing to pro-
8
vide eligible product developers with suffi-
9
cient quantities of a covered product on 
10
commercially 
reasonable, 
market-based 
11
terms, if the court finds, by a preponder-
12
ance of the evidence— 
13
(I) that the license holder delayed 
14
providing sufficient quantities of the 
15
covered product to the eligible product 
16
developer without a legitimate busi-
17
ness justification; or 
18
(II) that the license holder failed 
19
to comply with an order issued under 
20
clause (i). 
21
(B) MAXIMUM
MONETARY
AMOUNT.—A 
22
monetary amount awarded under subparagraph 
23
(A)(iii) shall not be greater than the revenue 
24
02:33 Aug 09, 2019
H3947
15 
•HR 3947 IH
that the license holder earned on the covered 
1
product during the period— 
2
(i) beginning on— 
3
(I) for a covered product that is 
4
not subject to a REMS with ETASU, 
5
the date that is 31 days after the date 
6
on which the license holder received 
7
the request; or 
8
(II) for a covered product that is 
9
subject to a REMS with ETASU, the 
10
date that is 31 days after the later 
11
of— 
12
(aa) the date on which the 
13
license holder received the re-
14
quest; or 
15
(bb) the date on which the 
16
license holder received a copy of 
17
the covered product authorization 
18
issued by the Secretary in ac-
19
cordance with paragraph (2)(B); 
20
and 
21
(ii) ending on the date on which the 
22
eligible product developer received suffi-
23
cient quantities of the covered product. 
24
02:33 Aug 09, 2019
H3947
16 
•HR 3947 IH
(C) AVOIDANCE
OF
DELAY.—The court 
1
may issue an order under subparagraph (A)(i) 
2
before conducting further proceedings that may 
3
be necessary to determine whether the eligible 
4
product developer is entitled to an award under 
5
clause (ii) or (iii) of subparagraph (A), or the 
6
amount of any such award. 
7
(c) LIMITATION OF LIABILITY.—A license holder for 
8
a covered product shall not be liable for any claim under 
9
Federal, State, or local law arising out of the failure of 
10
an eligible product developer to follow adequate safeguards 
11
to assure safe use of the covered product during develop-
12
ment or testing activities described in this section, includ-
13
ing transportation, handling, use, or disposal of the cov-
14
ered product by the eligible product developer. 
15
(d) NO VIOLATION OF REMS.—Section 505–1 of the 
16
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355– 
17
1) is amended by adding at the end the following new sub-
18
section: 
19
‘‘(l) PROVISION OF SAMPLES NOT A VIOLATION OF 
20
STRATEGY.—The provision of samples of a covered prod-
21
uct to an eligible product developer (as those terms are 
22
defined in section 2(a) of the Creating and Restoring 
23
Equal Access to Equivalent Samples Act of 2019) shall 
24
not be considered a violation of the requirements of any 
25
02:33 Aug 09, 2019
H3947
17 
•HR 3947 IH
risk evaluation and mitigation strategy that may be in 
1
place under this section for such drug.’’. 
2
(e) RULE OF CONSTRUCTION.— 
3
(1) DEFINITION.—In this subsection, the term 
4
‘‘antitrust laws’’— 
5
(A) has the meaning given the term in 
6
subsection (a) of the first section of the Clayton 
7
Act (15 U.S.C. 12); and 
8
(B) includes section 5 of the Federal 
9
Trade Commission Act (15 U.S.C. 45) to the 
10
extent that such section applies to unfair meth-
11
ods of competition. 
12
(2) ANTITRUST LAWS.—Nothing in this section 
13
shall be construed to limit the operation of any pro-
14
vision of the antitrust laws. 
15
SEC. 102. REMS APPROVAL PROCESS FOR SUBSEQUENT 
16
FILERS. 
17
Section 505–1 of the Federal Food, Drug, and Cos-
18
metic Act (21 U.S.C. 355–1), as amended by section 101, 
19
is further amended— 
20
(1) in subsection (g)(4)(B)— 
21
(A) in clause (i) by striking ‘‘or’’ after the 
22
semicolon; 
23
(B) in clause (ii) by striking the period at 
24
the end and inserting ‘‘; or’’; and 
25
02:33 Aug 09, 2019
H3947
18 
•HR 3947 IH
(C) by adding at the end the following: 
1
‘‘(iii) accommodate different, com-
2
parable aspects of the elements to assure 
3
safe use for a drug that is the subject of 
4
an application under section 505(j), and 
5
the applicable listed drug.’’; 
6
(2) in subsection (i)(1), by striking subpara-
7
graph (C) and inserting the following: 
8
‘‘(C)(i) Elements to assure safe use, if re-
9
quired under subsection (f) for the listed drug, 
10
which, subject to clause (ii), for a drug that is 
11
the subject of an application under section 
12
505(j) may use— 
13
‘‘(I) a single, shared system with the 
14
listed drug under subsection (f); or 
15
‘‘(II) a different, comparable aspect of 
16
the elements to assure safe use under sub-
17
section (f). 
18
‘‘(ii) The Secretary may require a drug 
19
that is the subject of an application under sec-
20
tion 505(j) and the listed drug to use a single, 
21
shared system under subsection (f), if the Sec-
22
retary determines that no different, comparable 
23
aspect of the elements to assure safe use could 
24
satisfy the requirements of subsection (f).’’; 
25
02:33 Aug 09, 2019
H3947
19 
•HR 3947 IH
(3) in subsection (i), by adding at the end the 
1
following: 
2
‘‘(3) SHARED
REMS.—If the Secretary ap-
3
proves, in accordance with paragraph (1)(C)(i)(II), a 
4
different, comparable aspect of the elements to as-
5
sure safe use under subsection (f) for a drug that 
6
is the subject of an abbreviated new drug application 
7
under section 505(j), the Secretary may require that 
8
such different comparable aspect of the elements to 
9
assure safe use can be used with respect to any 
10
other drug that is the subject of an application 
11
under section 505(j) or 505(b) that references the 
12
same listed drug.’’; and 
13
(4) by adding at the end the following: 
14
‘‘(m) SEPARATE REMS.—When used in this section, 
15
the terms ‘different, comparable aspect of the elements to 
16
assure safe use’ or ‘different, comparable approved risk 
17
evaluation and mitigation strategies’ means a risk evalua-
18
tion and mitigation strategy for a drug that is the subject 
19
of an application under section 505(j) that uses different 
20
methods or operational means than the strategy required 
21
under subsection (a) for the applicable listed drug, or 
22
other application under section 505(j) with the same such 
23
listed drug, but achieves the same level of safety as such 
24
strategy.’’. 
25
02:33 Aug 09, 2019
H3947
20 
•HR 3947 IH
TITLE II—INCREASING ACCESS 
1
TO DRUGS AND BIOSIMILAR 
2
PRODUCTS 
3
SEC. 201. EXPEDITED DEVELOPMENT AND PRIORITY RE-
4
VIEW FOR GENERIC COMPLEX DRUG PROD-
5
UCTS. 
6
Subchapter A of chapter V of the Federal Food, 
7
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
8
ed by adding at the end the following: 
9
‘‘SEC. 524B. EXPEDITED DEVELOPMENT AND PRIORITY RE-
10
VIEW FOR GENERIC COMPLEX DRUG PROD-
11
UCTS. 
12
‘‘(a) ESTABLISHMENT OF PROGRAM.—The Secretary 
13
shall establish a program to expedite the development of, 
14
and provide priority review under section 505(j) for, ge-
15
neric complex drug products. 
16
‘‘(b) REQUEST FOR DESIGNATION.—A sponsor of a 
17
generic complex drug product may request that the Sec-
18
retary designate such product for expedited development 
19
and priority review under this section. 
20
‘‘(c) DESIGNATION PROCESS.— 
21
‘‘(1) IN GENERAL.—Not later than 60 calendar 
22
days after the receipt of a request under subsection 
23
(c), the Secretary shall determine whether the prod-
24
uct that is the subject of the request meets the cri-
25
02:33 Aug 09, 2019
H3947
21 
•HR 3947 IH
teria under subsection (e) to be considered a generic 
1
complex drug product. If the Secretary determines 
2
that the product meets the criteria, the Secretary 
3
shall designate the product for expedited develop-
4
ment and priority review. 
5
‘‘(2) REVIEW.—Review of a request under sub-
6
section (b) shall be undertaken by a team that is 
7
composed of experienced staff and senior managers 
8
of the Food and Drug Administration. 
9
‘‘(3) WITHDRAWAL.—The Secretary may not 
10
withdraw a designation granted under this section 
11
on the basis of the criteria under subsection (e) no 
12
longer applying because of the subsequent clearance 
13
or approval of any other product. 
14
‘‘(d) EXPEDITED DEVELOPMENT AND PRIORITY RE-
15
VIEW GUIDANCE.— 
16
‘‘(1) CONTENT.—Not later than December 31, 
17
2021, the Secretary shall issue guidance on the im-
18
plementation of this section. Such guidance shall— 
19
‘‘(A) set forth the process by which a per-
20
son may seek a designation under subsection 
21
(c); 
22
‘‘(B) provide a template for requests under 
23
subsection (b); 
24
02:33 Aug 09, 2019
H3947
22 
•HR 3947 IH
‘‘(C) identify the criteria the Secretary will 
1
use in evaluating a request for designation 
2
under this section; and 
3
‘‘(D) identify the criteria and processes the 
4
Secretary will use to expedite the development 
5
and review of products designated under this 
6
section. 
7
‘‘(2) PROCESS.—Prior to finalizing the guid-
8
ance under paragraph (1), the Secretary shall seek 
9
public comment on a draft version of that guidance. 
10
‘‘(e) GENERIC
COMPLEX
DRUG
PRODUCT
DE-
11
FINED.—In this section, the term ‘generic complex drug 
12
product’ means a product that represents a complex ther-
13
apy that consists of or includes a drug for approval under 
14
section 505(j) and that— 
15
‘‘(1)(A) contains complex active ingredients 
16
(such as peptides, polymeric compounds, complex 
17
mixtures of active ingredients, and naturally sourced 
18
ingredients); 
19
‘‘(B) is composed of complex formulations (such 
20
as liposomes or colloids); 
21
‘‘(C) requires a complex route of delivery (such 
22
as locally acting drugs such as dermatological prod-
23
ucts and complex ophthalmological products and otic 
24
02:33 Aug 09, 2019
H3947
23 
•HR 3947 IH
dosage forms that are formulated as suspensions, 
1
emulsions, or gels); or 
2
‘‘(D) involves a complex dosage form (such as 
3
transdermals, metered dose inhalers, or extended re-
4
lease injectables); 
5
‘‘(2) presents as a complex drug-device com-
6
bination product (such as auto injectors or metered 
7
dose inhalers); or 
8
‘‘(3) is a product that would benefit from early 
9
scientific engagement due to complexity or uncer-
10
tainty concerning the approval pathway under sec-
11
tion 505(j).’’. 
12
SEC. 202. INCREASING PHARMACEUTICAL OPTIONS TO 
13
TREAT AN UNMET MEDICAL NEED. 
14
Subsection (b) of section 506 of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 356) is amended by 
16
adding at the end the following: 
17
‘‘(4) UNMET MEDICAL NEED.—For purposes of 
18
paragraph (1), a drug shall be deemed to address an 
19
unmet medical need for a disease or condition if 
20
fewer than 3 available drugs exist for the treatment 
21
of such disease or condition.’’. 
22
02:33 Aug 09, 2019
H3947
24 
•HR 3947 IH
SEC. 203. PREEMPTION OF STATE BARRIERS TO THE SUB-
1
STITUTION OF BIOSIMILAR PRODUCTS. 
2
No State, or any political subdivision thereof, may 
3
prohibit a pharmacy or pharmacist from dispensing, in 
4
place of a biological reference product, any product that, 
5
pursuant to section 351(k) of the Public Health Service 
6
Act (42 U.S.C. 262(k)), has been determined by the Sec-
7
retary of Health and Human Services to be interchange-
8
able with the reference product in accordance with sub-
9
sections (a) and (k)(4) of such Act (42 U.S.C. 262(a), 
10
(k)(4)). 
11
SEC. 204. EXPEDITED PROCESS FOR BIOLOGICAL PROD-
12
UCTS AUTHORIZED FOR MARKETING IN EU-
13
ROPEAN UNION. 
14
Section 351(a) of the Public Health Service Act (42 
15
U.S.C. 262(a)) is amended by adding at the end the fol-
16
lowing new paragraph: 
17
‘‘(4) PRODUCTS AUTHORIZED FOR MARKETING 
18
IN EUROPEAN UNION.—In considering whether to li-
19
cense a biological product under this subsection or 
20
subsection (k), the Secretary may expedite the li-
21
censing process if the biological product has been 
22
authorized for marketing by the European Medicines 
23
Agency and such authorization remains in effect.’’. 
24
21:23 Aug 14, 2019
H3947
25 
•HR 3947 IH
TITLE III—PRESCRIPTION DRUG 
1
PRICING AND COMPETITION 
2
SEC. 301. MEDICARE DRUG COVERAGE. 
3
Notwithstanding any other provision of law, the Sec-
4
retary of Health and Human Services may alter payments 
5
for prescription drugs, including biologicals, provided 
6
through the Medicare part B program by paying at rates 
7
that, based on the average sales price plus 6 percent in 
8
the year of implementation of this Act, grow at the con-
9
sumer price index (CPI Prescription Drugs). 
10
SEC. 302. FEE TRANSPARENCY BETWEEN PHARMACIES AND 
11
PBMS. 
12
(a) PROHIBITING MEDICARE PDP SPONSORS AND 
13
MA–PD ORGANIZATIONS FROM RETROACTIVELY REDUC-
14
ING PAYMENT ON CLEAN CLAIMS SUBMITTED BY PHAR-
15
MACIES.— 
16
(1) IN GENERAL.—Section 1860D–12(b)(4)(A) 
17
of the Social Security Act (42 U.S.C. 1395w– 
18
112(b)(4)(A)) is amended by adding at the end the 
19
following new clause: 
20
‘‘(iv) PROHIBITING RETROACTIVE RE-
21
DUCTIONS
IN
PAYMENTS
ON
CLEAN 
22
CLAIMS.—Each contract entered into with 
23
a PDP sponsor under this part with re-
24
spect to a prescription drug plan offered 
25
20:27 Aug 09, 2019
H3947
26 
•HR 3947 IH
by such sponsor shall provide that after 
1
the date of receipt of a clean claim sub-
2
mitted by a pharmacy, the PDP sponsor 
3
(or an agent of the PDP sponsor) may not 
4
retroactively reduce payment on such claim 
5
directly or indirectly through aggregated 
6
effective rate or otherwise except in the 
7
case such claim is found to not be a clean 
8
claim (such as in the case of a claim lack-
9
ing required substantiating documentation) 
10
during the course of a routine audit as 
11
permitted pursuant to written agreement 
12
between the PDP sponsor (or such an 
13
agent) and such pharmacy. The previous 
14
sentence shall not prohibit any retroactive 
15
increase in payment to a pharmacy pursu-
16
ant to a written agreement between a PDP 
17
sponsor (or an agent of such sponsor) and 
18
such pharmacy.’’. 
19
(2) EFFECTIVE DATE.—The amendment made 
20
by subsection (a) shall apply with respect to con-
21
tracts entered into on or after January 1, 2021. 
22
(b) ELIMINATION OF DIR FEES.— 
23
02:33 Aug 09, 2019
H3947
27 
•HR 3947 IH
(1) PHARMACY
BENEFITS
MANAGER
STAND-
1
ARDS UNDER THE MEDICARE PROGRAM FOR PRE-
2
SCRIPTION DRUG PLANS AND MA–PD PLANS.— 
3
(A) IN
GENERAL.—Section 1860D–12(b) 
4
of the Social Security Act (42 U.S.C. 1395w– 
5
112(b)) is amended by adding at the end the 
6
following new paragraph: 
7
‘‘(7) PHARMACY
BENEFITS
MANAGER
TRANS-
8
PARENCY
REQUIREMENTS.—Each contract entered 
9
into with a PDP sponsor under this part with re-
10
spect to a prescription drug plan offered by such 
11
sponsor or with an MA organization offering an 
12
MA–PD plan under part C shall provide that the 
13
sponsor or organization, respectively, may not enter 
14
into a contract with any pharmacy benefits manager 
15
(referred to in this paragraph as a ‘PBM’) to man-
16
age the prescription drug coverage provided under 
17
such plan, or to control the costs of the prescription 
18
drug coverage under such plan, unless the PBM ad-
19
heres to the following criteria when handling person-
20
ally identifiable utilization and claims data or other 
21
sensitive patient data: 
22
‘‘(A) The PBM may not transmit any per-
23
sonally identifiable utilization, protected health 
24
information, or claims data, with respect to a 
25
02:33 Aug 09, 2019
H3947
28 
•HR 3947 IH
plan enrollee, to a pharmacy owned by a PBM 
1
if the plan enrollee has not voluntarily elected 
2
in writing or via secure electronic means to fill 
3
that particular prescription at the PBM-owned 
4
pharmacy. 
5
‘‘(B) The PBM may not require that a 
6
plan enrollee use a retail pharmacy, mail order 
7
pharmacy, specialty pharmacy, or other phar-
8
macy entity providing pharmacy services in 
9
which the PBM has an ownership interest or 
10
that has an ownership interest in the PBM, or 
11
provide an incentive to a plan enrollee to en-
12
courage the enrollee to use a retail pharmacy, 
13
mail order pharmacy, specialty pharmacy, or 
14
other pharmacy entity providing pharmacy serv-
15
ices in which the PBM has an ownership inter-
16
est or that has an ownership interest in the 
17
PBM, if the incentive is applicable only to such 
18
pharmacies.’’. 
19
(B) REGULAR UPDATE OF PRESCRIPTION 
20
DRUG PRICING STANDARD.—Paragraph (6) of 
21
section 1860D–12(b) of the Social Security Act 
22
(42 U.S.C. 1395w–112(b)) is amended to read 
23
as follows: 
24
02:33 Aug 09, 2019
H3947
29 
•HR 3947 IH
‘‘(6) REGULAR
UPDATE
OF
PRESCRIPTION 
1
DRUG PRICING STANDARD.— 
2
‘‘(A) IN GENERAL.—If the PDP sponsor of 
3
a prescription drug plan (or MA organization 
4
offering an MA–PD plan) uses a standard for 
5
reimbursement (as described in subparagraph 
6
(B)) of pharmacies based on the cost of a drug, 
7
each contract entered into with such sponsor 
8
under this part (or organization under part C) 
9
with respect to the plan shall provide that the 
10
sponsor (or organization) shall— 
11
‘‘(i) update such standard not less fre-
12
quently than once every 7 days, beginning 
13
with an initial update on January 1 of 
14
each year, to accurately reflect the market 
15
price of acquiring the drug; 
16
‘‘(ii) disclose to applicable pharmacies 
17
and the contracting entities of such phar-
18
macies the sources used for making any 
19
such update immediately without require-
20
ment of request; 
21
‘‘(iii) if the source for such a standard 
22
for reimbursement is not publicly available, 
23
disclose to the applicable pharmacies and 
24
the respective contracting entities of such 
25
02:33 Aug 09, 2019
H3947
30 
•HR 3947 IH
pharmacies all individual drug prices to be 
1
so updated in advance of the use of such 
2
prices for the reimbursement of claims; 
3
‘‘(iv) establish a process to appeal, in-
4
vestigate, and resolve disputes regarding 
5
individual drug prices that are less than 
6
the pharmacy acquisition price for such 
7
drug, which must be adjudicated within 7 
8
days of the pharmacy filing its appeal; and 
9
‘‘(v) provide all such pricing data in 
10
an .xml spreadsheet format or a com-
11
parable easily accessible and complete 
12
spreadsheet format. 
13
‘‘(B) 
PRESCRIPTION
DRUG
PRICING 
14
STANDARD
DEFINED.—For purposes of sub-
15
paragraph (A), a standard for reimbursement 
16
of a pharmacy is any methodology or formula 
17
for varying the pricing of a drug or drugs dur-
18
ing the term of the pharmacy reimbursement 
19
contract that is based on the cost of the drug 
20
involved, including drug pricing references and 
21
amounts that are based upon average wholesale 
22
price, wholesale average cost, average manufac-
23
turer price, average sales price, maximum al-
24
02:33 Aug 09, 2019
H3947
31 
•HR 3947 IH
lowable cost (MAC), or other costs, whether 
1
publicly available or not.’’. 
2
(C) EFFECTIVE DATE.—The amendments 
3
made by this section shall apply to plan years 
4
beginning on or after January 1, 2020. 
5
(2) REGULAR UPDATE OF PRESCRIPTION DRUG 
6
PRICING STANDARD UNDER TRICARE RETAIL PHAR-
7
MACY
PROGRAM.—Section 1074g(d) of title 10, 
8
United States Code, is amended by adding at the 
9
end the following new paragraph: 
10
‘‘(3) To the extent practicable, with respect to the 
11
TRICARE retail pharmacy program described in sub-
12
section (a)(2)(E)(ii), the Secretary shall ensure that a con-
13
tract entered into with a TRICARE managed care support 
14
contractor includes requirements described in section 
15
1860D–12(b)(6) of the Social Security Act (42 U.S.C. 
16
1395w–112(b)(6)) to ensure the provision of information 
17
regarding the pricing standard for prescription drugs.’’. 
18
(3) PRESCRIPTION
DRUG
TRANSPARENCY
IN 
19
THE FEDERAL EMPLOYEES HEALTH BENEFITS PRO-
20
GRAM.— 
21
(A) IN GENERAL.—Section 8902 of title 5, 
22
United States Code, is amended by adding at 
23
the end the following new subsections: 
24
02:33 Aug 09, 2019
H3947
32 
•HR 3947 IH
‘‘(p) A contract may not be made or a plan approved 
1
under this chapter under which a carrier has an agree-
2
ment with a pharmacy benefits manager (in this sub-
3
section referred to as a ‘PBM’) to manage prescription 
4
drug coverage or to control the costs of the prescription 
5
drug coverage unless the carrier and PBM adhere to the 
6
following criteria: 
7
‘‘(1) The PBM may not transmit any personally 
8
identifiable utilization, protected health information, 
9
or claims data with respect to an individual enrolled 
10
under such contract or plan to a pharmacy owned by 
11
the PBM if the individual has not voluntarily elected 
12
in writing or via secure electronic means to fill that 
13
particular prescription at such a pharmacy. 
14
‘‘(2) The PBM may not require that an indi-
15
vidual enrolled under such contract or plan use a re-
16
tail pharmacy, mail order pharmacy, specialty phar-
17
macy, or other pharmacy entity providing pharmacy 
18
services in which the PBM has an ownership interest 
19
or that has an ownership interest in the PBM or 
20
provide an incentive to a plan enrollee to encourage 
21
the enrollee to use a retail pharmacy, mail order 
22
pharmacy, specialty pharmacy, or other pharmacy 
23
entity providing pharmacy services in which the 
24
PBM has an ownership interest or that has an own-
25
02:33 Aug 09, 2019
H3947
33 
•HR 3947 IH
ership interest in the PBM, if the incentive is appli-
1
cable only to such pharmacies. 
2
‘‘(q)(1) If a contract made or plan approved under 
3
this chapter provides for a standard for reimbursement 
4
(as described in paragraph (2)) with respect to a prescrip-
5
tion drug plan, such contract or plan shall provide that 
6
the applicable carrier— 
7
‘‘(A) update such standard not less frequently 
8
than once every 7 days, beginning with an initial up-
9
date on January 1 of each year, to accurately reflect 
10
the market price of acquiring the drug; 
11
‘‘(B) disclose to applicable pharmacies and the 
12
contracting entities of such pharmacies the sources 
13
used for making any such update immediately with-
14
out requirement of request; 
15
‘‘(C) if the source for such a standard for reim-
16
bursement is not publicly available, disclose to the 
17
applicable pharmacies and contracting entities of 
18
such pharmacies all individual drug prices to be so 
19
updated in advance of the use of such prices for the 
20
reimbursement of claims; 
21
‘‘(D) establish a process to appeal, investigate, 
22
and resolve disputes regarding individual drug prices 
23
that are less than the pharmacy acquisition price for 
24
02:33 Aug 09, 2019
H3947
34 
•HR 3947 IH
such drug, which must be adjudicated within 7 days 
1
of the pharmacy filing its appeal; and 
2
‘‘(E) provide all such pricing data in an .xml 
3
spreadsheet format or a comparable easily accessible 
4
and complete spreadsheet format. 
5
‘‘(2) For purposes of paragraph (1), a standard for 
6
reimbursement of a pharmacy is any methodology or for-
7
mula for varying the pricing of a drug or drugs during 
8
the term of the pharmacy reimbursement contract that is 
9
based on the cost of the drug involved, including drug pric-
10
ing references and amounts that are based upon average 
11
wholesale price, wholesale average cost, average manufac-
12
turer price, average sales price, maximum allowable cost, 
13
or other costs, whether publicly available or not.’’. 
14
(B) APPLICATION.—The amendment made 
15
by subparagraph (A) shall apply to any contract 
16
entered into under section 8902 of title 5, 
17
United States Code, on or after the date of en-
18
actment of this section. 
19
SEC. 303. SUNSET OF LIMIT ON MAXIMUM REBATE AMOUNT 
20
FOR SINGLE SOURCE DRUGS AND INNO-
21
VATOR MULTIPLE SOURCE DRUGS. 
22
Section 1927(c)(2)(D) of the Social Security Act (42 
23
U.S.C. 1396r–8(c)(2)(D)) is amended by inserting after 
24
02:33 Aug 09, 2019
H3947
35 
•HR 3947 IH
‘‘December 31, 2009,’’ the following: ‘‘and before Decem-
1
ber 31, 2024,’’. 
2
SEC. 304. REGULATION OF MANUFACTURER-SPONSORED 
3
COPAY CONTRIBUTIONS. 
4
Notwithstanding any other provision of law, the Sec-
5
retary of Health and Human Services may establish a 
6
mechanism prohibiting drug manufacturers from contrib-
7
uting financially to patient copays, and establish a system 
8
of penalizing such behavior. 
9
TITLE IV—PATENT DISCLOSURE 
10
REQUIREMENTS 
11
SEC. 401. PATENT DISCLOSURE AND TRANSPARENCY RE-
12
QUIREMENTS. 
13
(a) IN GENERAL.— 
14
(1) IN GENERAL.—Section 351 of the Public 
15
Health Service Act (42 U.S.C. 262) is amended by 
16
adding at the end the following: 
17
‘‘(o) ADDITIONAL REQUIREMENTS WITH RESPECT 
18
TO PATENTS.— 
19
‘‘(1) PUBLICATION OF INFORMATION.— 
20
‘‘(A) IN GENERAL.—Within 1 year of the 
21
date of enactment of the Biologic Patent Trans-
22
parency Act, the Secretary shall publish and 
23
make available to the public a single, easily 
24
searchable list that includes— 
25
02:33 Aug 09, 2019
H3947
36 
•HR 3947 IH
‘‘(i) the proper and proprietary name 
1
of each biological product licensed or 
2
deemed to be licensed under subsection (a) 
3
or (k); 
4
‘‘(ii) the date of approval and applica-
5
tion number for each such biological prod-
6
uct; 
7
‘‘(iii) the marketing status, dosage 
8
form, route of administration, strength, 
9
and, if applicable, reference product, for 
10
each such biological product; 
11
‘‘(iv) the licensure status for each 
12
such biological product, including whether 
13
the license at the time of listing is ap-
14
proved, withdrawn, or revoked; 
15
‘‘(v) for each such biological product 
16
that is a reference product for which an 
17
exclusivity period applies, and for which 
18
the Secretary has determined the dates of 
19
such exclusivity period, under subsection 
20
(k)(7)(A) or subsection (k)(7)(B) of this 
21
section or under section 527 of the Federal 
22
Food, Drug, and Cosmetic Act, including 
23
any extension of such exclusivity period in 
24
accordance with subsection (m) of this sec-
25
02:33 Aug 09, 2019
H3947
37 
•HR 3947 IH
tion, the date on which such exclusivity pe-
1
riod expires; 
2
‘‘(vi) any determination of biosimi-
3
larity or interchangeability for each such 
4
biological product; and 
5
‘‘(vii) information regarding approved 
6
indications for each such biological prod-
7
uct, in such manner as the Secretary de-
8
termines appropriate. 
9
‘‘(B) UPDATES.—Every 30 days after the 
10
publication of the first list under subparagraph 
11
(A), the Secretary shall revise the list to in-
12
clude— 
13
‘‘(i)(I) each biological product licensed 
14
under subsection (a) or (k) during the 30- 
15
day period; and 
16
‘‘(II) with respect to each biological 
17
product described in subclause (I), the in-
18
formation described in clauses (i) through 
19
(vii) of subparagraph (A); and 
20
‘‘(ii) any updates to information pre-
21
viously published in accordance with sub-
22
paragraph (A).’’. 
23
(2) PUBLIC
LISTING
OF
PATENT
INFORMA-
24
TION.— 
25
02:33 Aug 09, 2019
H3947
38 
•HR 3947 IH
(A) 
IN
GENERAL.—The 
Secretary 
of 
1
Health and Human Services shall include in the 
2
recommendations 
transmitted 
to 
Congress 
3
under section 744I(f) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 379j–53(f)) 
5
recommendations with respect to the collection 
6
and publication of patent information in the list 
7
described in section 351(o) of the Public Health 
8
Service Act (42 U.S.C. 262), as added by para-
9
graph (1). 
10
(B) DEVELOPMENT.—In developing rec-
11
ommendations under subparagraph (A), the 
12
Secretary of Health and Human Services may 
13
consult with the Federal Trade Commission, 
14
the Director of the United States Patent and 
15
Trademark Office, and the Federal Trade Com-
16
mission, in addition to the entities listed in sec-
17
tion 744I(f)(1) of the Federal Food, Drug, and 
18
Cosmetic Act (21 U.S.C. 379j–53(f)(1)). 
19
(b) RULE OF CONSTRUCTION.—Nothing in this sec-
20
tion, including the amendment made by this section, shall 
21
be construed to require or allow the Secretary of Health 
22
and Human Services to delay the review or approval of 
23
a biologic license application under section 351 of the Pub-
24
lic Health Service Act (42 U.S.C. 262). 
25
02:33 Aug 09, 2019
H3947
39 
•HR 3947 IH
SEC. 402. ANTITRUST EXEMPTION FOR HEALTH INSURANCE 
1
ISSUERS TO NEGOTIATE WHOLESALE ACQUI-
2
SITION PRICES OF PRESCRIPTION DRUGS 
3
PURCHASED FROM DRUG MANUFACTURERS. 
4
(a) EXEMPTION.—It shall not be a violation of the 
5
antitrust laws for one or more health insurance issuers 
6
or their designated agents to jointly negotiate wholesale 
7
acquisition prices of a prescription drug with a manufac-
8
turer of a prescription drug with regards to the reimburse-
9
ment policies of the insurers of the manufacturer’s drugs 
10
so long as no single wholesale acquisition price is jointly 
11
determined between the insurance issuers or their des-
12
ignated agents. 
13
(b) DEFINITIONS.—For purposes of this section: 
14
(1) ANTITRUST
LAWS.—The term ‘‘antitrust 
15
laws’’ has the meaning given it in subsection (a) of 
16
the 1st section of the Clayton Act (15 U.S.C. 12(a)), 
17
except that such term includes section 5 of the Fed-
18
eral Trade Commission Act (15 U.S.C. 45) to the 
19
extent such section 5 applies to unfair methods of 
20
competition. 
21
(2) HEALTH
INSURANCE
ISSUER.—The term 
22
‘‘health insurance issuer’’ has the meaning given 
23
that term in section 2791(b) of the Public Health 
24
Service Act (42 U.S.C. 300gg–91(b)). 
25
02:33 Aug 09, 2019
H3947
40 
•HR 3947 IH
(3) HEALTH MAINTENANCE ORGANIZATION.— 
1
The 
term 
‘‘health 
maintenance 
organization’’ 
2
means— 
3
(A) a federally qualified health mainte-
4
nance organization (as defined in section 
5
300e(a) of title 42 of the Code of Federal Reg-
6
ulations), 
7
(B) an organization recognized under State 
8
law as a health maintenance organization, or 
9
(C) a similar organization regulated under 
10
State law for solvency in the same manner and 
11
to the same extent as such a health mainte-
12
nance organization. 
13
(4) MANUFACTURER.—The term ‘‘manufac-
14
turer’’ means anyone who is engaged in manufac-
15
turing, preparing, propagating, compounding, proc-
16
essing, packaging, repackaging, or labeling of a pre-
17
scription drug. 
18
(5) PRESCRIPTION DRUG.—The term ‘‘prescrip-
19
tion drug’’ means a drug for human use subject to 
20
section 503(b)(1) of the Federal Food, Drug, and 
21
Cosmetic Act (21 U.S.C. 353(b)(1)). 
22
(c) EFFECTIVE DATE.—This section shall take effect 
23
on the date of the enactment of this Act but shall not 
24
apply with respect to conduct that occurs before such date. 
25
02:33 Aug 09, 2019
H3947
41 
•HR 3947 IH
SEC. 403. FAIR TREATMENT OF MEDICARE PART B BILLING 
1
CODES 
FOR 
THE 
PRESCRIBING 
OF 
2
BIOSIMILARS. 
3
Section 1847A of the Social Security Act (42 U.S.C. 
4
1395w–3a) is amended by adding at the end the following 
5
new subsection: 
6
‘‘(h) USE
OF CERTAIN CODES.—Notwithstanding 
7
any previous provision of this section, for purposes of pay-
8
ment of biological biosimilar product the Secretary of 
9
Health and Human Services shall assign a uniform Com-
10
mon Procedure System code to describe all such products 
11
that share a common reference product.’’. 
12
TITLE V—FIXING GLOBAL 
13
FREELOADING 
14
SEC. 501. CHIEF PHARMACEUTICAL NEGOTIATOR IN THE 
15
OFFICE OF THE UNITED STATES TRADE REP-
16
RESENTATIVE. 
17
(a) IN GENERAL.—Section 141 of the Trade Act of 
18
1974 (19 U.S.C. 2171) is amended— 
19
(1) in subsection (b)(2)— 
20
(A) by striking ‘‘and one Chief Innovation 
21
and Intellectual Property Negotiator’’ and in-
22
serting ‘‘one Chief Innovation and Intellectual 
23
Property Negotiator, and one Chief Pharma-
24
ceutical Negotiator’’; 
25
21:23 Aug 14, 2019
H3947
42 
•HR 3947 IH
(B) by striking ‘‘or the Chief Innovation 
1
and Intellectual Property Negotiator’’ and in-
2
serting ‘‘the Chief Innovation and Intellectual 
3
Property Negotiator, or the Chief Pharma-
4
ceutical Negotiator’’; and 
5
(C) by striking ‘‘and the Chief Innovation 
6
and Intellectual Property Negotiator’’ and in-
7
serting ‘‘the Chief Innovation and Intellectual 
8
Property Negotiator, and the Chief Pharma-
9
ceutical Negotiator’’; and 
10
(2) in subsection (c), by adding at the end the 
11
following new paragraph: 
12
‘‘(7) The principal function of the Chief Phar-
13
maceutical Negotiator shall be to conduct trade ne-
14
gotiations and to enforce trade agreements relating 
15
to United States pharmaceutical products and serv-
16
ices. The Chief Pharmaceutical Negotiator shall be 
17
a vigorous advocate on behalf of United States phar-
18
maceutical interests, including patients and United 
19
States pharmaceutical workers. The Chief Pharma-
20
ceutical Negotiator shall perform such other func-
21
tions as the United States Trade Representative 
22
may direct.’’. 
23
(b) COMPENSATION.—Section 5314 of title 5, United 
24
States Code is amended by striking ‘‘Chief Innovation and 
25
02:33 Aug 09, 2019
H3947
43 
•HR 3947 IH
Intellectual Property Negotiator, Office of the United 
1
States Trade Representative.’’ and inserting the following: 
2
‘‘Chief Innovation and Intellectual Property Nego-
3
tiator, Office of the United States Trade Representative. 
4
‘‘Chief Pharmaceutical Negotiator, Office of the 
5
United States Trade Representative.’’. 
6
(c) REPORT REQUIRED.—Not later than one year 
7
after the appointment of the first Chief Pharmaceutical 
8
Negotiator pursuant to paragraph (2) of section 141(b) 
9
of the Trade Act of 1974, as amended by subsection (a), 
10
and annually thereafter, the United States Trade Rep-
11
resentative shall submit to the Committee on Finance of 
12
the Senate and the Committee on Ways and Means of the 
13
House of Representatives a report describing in detail— 
14
(1) enforcement actions taken by the Trade 
15
Representative during the one-year period preceding 
16
the submission of the report to ensure the protection 
17
of United States pharmaceutical products and serv-
18
ices; and 
19
(2) other actions taken by the Trade Represent-
20
ative to advance United States pharmaceutical prod-
21
ucts and services. 
22
Æ 
02:33 Aug 09, 2019
H3947
